BioLineRx (BLRX) Capital Expenditures (2013 - 2024)
BioLineRx (BLRX) recorded quarterly Capital Expenditures of $6000.0 in Q4 2024, up 122.22% quarter-over-quarter from -$27000.0 in Q2 2024, and up 137.5% on a YoY basis from $2526.3 in Q1 2024.
BioLineRx (BLRX) Capital Expenditures (2013 - 2024) Analysis & Trends
BioLineRx's Capital Expenditures history runs 12 years deep, the most recent figure standing at $6000.0 for Q4 2024.
- In Q4 2024, Capital Expenditures rose 137.5% year-over-year to $6000.0; the TTM figure through Dec 2024 stood at -$53000.0 (up 54.31% YoY), while the FY2025 annual figure was -$25000.0, up 52.83% from the prior year.
- Capital Expenditures was $6000.0 for Q4 2024 at BioLineRx, up from -$27000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $6000.0 in Q4 2024 to a low of -$67000.0 in Q2 2023.
- Historically, Capital Expenditures has averaged -$24750.0 across 5 years, with a median of -$19000.0 in 2021.
- The sharpest annual moves came in 2021 and 2024: Capital Expenditures plunged 6300.0% in 2021, then jumped 137.5% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $1000.0 in 2020, then slumped by 6300.0% to -$62000.0 in 2021, then advanced by 8.06% to -$57000.0 in 2022, then jumped by 71.93% to -$16000.0 in 2023, then surged by 137.5% to $6000.0 in 2024.
- The last three Capital Expenditures figures came in at $6000.0 (Q4 2024), -$27000.0 (Q2 2024), and -$32000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -57,000.00 |
| Dec 31, 2022 | -57,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Jun 30, 2022 | -44,000.00 |
| Jun 30, 2022 | -44,000.00 |